Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.
about
The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial LesionsQuality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation StudyClinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR).In vivo evidence for an endothelium-dependent mechanism in radiation-induced normal tissue injury.Image-guided high-dose-rate brachytherapy: preliminary outcomes and toxicity of a joint interventional radiology and radiation oncology technique for achieving local control in challenging casesStereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design.Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.A Treatment Planning Study of Stereotactic Body Radiotherapy for Atrial Fibrillation.Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.Hypofractionated radiotherapy for localized prostate cancer.Hypofractionated radiotherapy for prostate cancer.A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction.Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.Clinical implementation of a knowledge based planning tool for prostate VMAT.Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?The Role of Hypofractionated Radiotherapy in Prostate Cancer.Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.Rectal Toxicity After Extremely Hypofractionated Radiotherapy Using a Non-Isocentric Robotic Radiosurgery System for Early Stage Prostate Cancer.A Phase II Study of Stereotactic Body Radiation Therapy for Low-Intermediate-High-Risk Prostate Cancer Using Helical Tomotherapy: Dose-Volumetric Parameters Predicting Early Toxicity.Simultaneous integrated protection : A new concept for high-precision radiation therapy.Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes.ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.Efficacy of a rectal spacer with prostate SABR - first UK experience.Technical Note: System for evaluating local hypothermia as a radioprotector of the rectum in a small animal model.Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?Stereotactic ablative body radiotherapy in patients with prostate cancerSalvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability modelsA quantitative assessment of the consequences of allowing dose heterogeneity in prostate radiation therapy planning
P2860
Q26770254-E213C326-7A81-472F-BC11-9FADD0EF544CQ34413524-8CEB0216-B17B-4E0D-9685-218C69FC36A7Q34575533-6C1B9F50-C612-4744-A9C2-4FACDA0A0B32Q35686316-199E2A96-A2FC-43A7-9A28-A80065767DF7Q36221698-FAF4D772-FB81-43F6-8906-7004B13D7608Q36328576-DD8E98C5-8096-4D7B-9807-75C501A1F8D6Q36426682-5D44075F-DE3B-455B-8A6C-1E360FC50035Q36535570-5A506811-220B-4560-B3E3-027CFCB07480Q37110245-B929E87D-08EC-49F6-9D34-2A997BDE23ADQ37175207-653520DE-62D6-4CC3-AD06-B7B182B93D3AQ37175452-6BF468DF-6AF3-4F64-AC80-B6EC5046B034Q37380104-10E67C16-EA04-4AB8-B2CA-7C89BE9FCE24Q37547386-7701ED05-AA59-4AB1-B59D-ADF898D27F9BQ38283897-105B2248-3828-48D5-9DC9-FA08A38AEF23Q38357722-138A7BF2-88ED-42F8-8FF0-F203E8B75393Q38362692-727CCE8C-CD54-4601-9F0F-38733872DD73Q38372450-F88E360C-05D3-434C-B945-0E190323AC9BQ38437266-165B302E-E429-4973-9BB2-66CEE9A75222Q38797630-5F191D9F-563A-4D4F-B9C1-7BD51CB3E785Q38863898-C0F1394B-6B4F-480E-9EF9-649AA0B6DF20Q39200876-68BBEF78-D934-4DC2-8BDA-0A0014C0EE3AQ41097227-7849DE94-6594-4123-8CEE-29FEE3057CE5Q41276603-8709C107-3753-4007-81A6-D1F8E2AB1B02Q41878672-2BB7B62D-9C61-4FC5-ADD5-E84D9FF5EECDQ41982995-EF5E55AC-51BB-4AE1-8D6E-3B79E3F00336Q42250155-FE68650D-47A5-4038-AC91-34D82E97FA0AQ42363621-ED1B08CF-8394-4AD5-AB30-8F1998D85352Q42857993-309D88D4-73E5-49E6-A451-34C2D9F75CAFQ43379694-1F2548C7-6AFE-4589-8767-89677CCCEEE6Q47226698-4CB4EF9D-FA88-4DEC-A472-C2C3F7864C90Q50641104-3095B7EB-2885-423F-92C6-DC6C975B3254Q55379685-04E7E46F-FFFE-4A5A-8F3E-3AE0EC143CEFQ57112486-7DF5AFFB-C07E-43F0-AB11-778EFC807EB0Q58131091-55B5B71D-815D-486D-8D0C-0788691B32A8Q58788241-330CA0F7-027B-4607-A00D-54C88FDEB594
P2860
Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Predictors of rectal tolerance ...... n therapy for prostate cancer.
@en
Predictors of rectal tolerance ...... n therapy for prostate cancer.
@nl
type
label
Predictors of rectal tolerance ...... n therapy for prostate cancer.
@en
Predictors of rectal tolerance ...... n therapy for prostate cancer.
@nl
prefLabel
Predictors of rectal tolerance ...... n therapy for prostate cancer.
@en
Predictors of rectal tolerance ...... n therapy for prostate cancer.
@nl
P2093
P921
P1476
Predictors of rectal tolerance ...... n therapy for prostate cancer.
@en
P2093
Akash Nanda
Alana Christie
Alida Perkins
Brian D Kavanagh
Christopher Straka
D W Nathan Kim
David Pistenmaa
David Raben
Jeffrey Brindle
L Chinsoo Cho
P304
P356
10.1016/J.IJROBP.2014.03.012
P407
P50
P577
2014-07-01T00:00:00Z